Document:

EXHIBIT 10.35

January 16, 2007

Lawrence A. Kenyon
654 Providence Lane
Lindenhurst, IL 60046

Dear Larry:

This will confirm the  employment  offer we made to you, and which you accepted,
for the position of Executive  Vice  President,  Chief  Financial  Officer,  and
Corporate Secretary of Alfacell  Corporation  reporting to Kuslima Shogen, Chief
Executive Officer. We look forward to working with you and are confident you can
add significant value to Alfacell.

This will confirm that your start date is January 16, 2007.  You will receive an
annual base salary of $210,000 and are  eligible to  participate  in  Alfacell's
bonus plan  pursuant to which you will be  eligible  to receive a  discretionary
annual  bonus of up to 20% of your base salary,  provided  that you are actively
employed on the bonus payout date.  The  discretionary  bonus may be tied to the
achievement of specific identified goals to be determined by Alfacell's Board of
Directors or a committee thereof.  Alfacell will provide you with the reasonable
cost of  temporary  housing for a period up to twelve (12)  months,  the cost of
round trip coach  airfare  from Newark to Chicago for up to twelve (12)  months,
and the  reasonable  cost of relocating  your household  effects.  You were also
granted a ten-year option,  pursuant to Alfacell's 2004 Stock Incentive Plan, to
purchase  375,000  shares of Alfacell's  common stock with an exercise  price of
$1.55 per share,  the closing  price of  Alfacell's  common stock on January 16,
2007, the date of grant. The option vested  immediately as to 75,000 shares, and
will vest as to the remaining shares in four equal annual installments of 75,000
shares on each anniversary of the grant date, beginning on January 16, 2008. You
will  receive an option  agreement  for this option  grant which is the standard
form of option  agreement  approved by the  Compensation  Committee  for options
granted to officers under the 2004 Stock Incentive Plan. As a full-time employee
you  are  eligible  to  participate  in  Alfacell  sponsored  benefit  programs,
including  participation in the Alfacell 401k program,  life and other insurance
programs subject to the terms and conditions of such programs. In addition,  you
will  receive  three (3) weeks paid  vacation.  The  foregoing  compensation  is
contingent  upon you working  full time for Alfacell and spending at least three
days per week in  Alfacell's  offices  and/or  on the road  with  management  or
investors.

Our employment  offer to you is contingent  upon: 1) your ability as required by
federal law to establish your employment eligibility;  as a U.S. citizen, a U.S.
lawful  permanent  resident,  or  an  individual   specifically  authorized  for
employment in the U.S. by the Immigration and Naturalization  Service and 2) you
signing and being subject to a standard form of  Confidentiality  and Inventions
Agreement.  Failure to meet any of these contingencies  outlined above will make
you ineligible for employment.

<PAGE>

As with all other Alfacell employees,  your employment is "at will", which means
either you or Alfacell may terminate your employment at any time for any reason.

Larry, we look forward to your addition as a member of the Alfacell team. Please
acknowledge this letter.

Sincerely,

/s/ Kuslima Shogen
------------------
Kuslima Shogen
Chief Executive Officer

ACKNOWLEDGMENT:

I have read,  understand  and  accept  the  foregoing  terms and  conditions  of
employment.  I further understand that while my salary,  benefits, job title and
job duties may change from time to time  without  written  modification  of this
agreement,  the at-will term of my  employment  (i.e.,  my right and  Alfacell's
right to terminate  our  employment  relationship  at any time,  with or without
cause) is a term of  employment  that  cannot be altered or  modified  except in
writing and signed by me and Alfacell's representative.

Name:  /s/ Lawrence A. Kenyon       Date:  January 16, 2007
       ----------------------              ----------------
       Lawrence A. KenyonEXHIBIT 10.36

                              ALFACELL CORPORATION

                    NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

                            Adopted February 8, 2007

      A summary of the  compensation  policy for the  non-employee  directors of
Alfacell Corporation (the "Company") follows:

<TABLE>
<S>                        <C>                 <C>
Annual Cash Retainer       $15,000             Paid in equal quarterly installments

Annual Option Retainer     20,000 options      2007 retainer previously granted in
                                               December 2006

Committee Chairperson      10,000 options      For each committee chaired

Committee Member           5,000 options       For each committee (unless chair of
                                               committee)

Vice Chairman              100% option bonus   Computation based on all options
                                               received by vice chair for
                                               board/committee memberships
</TABLE>

      The cash payments were  effective as of January 1, 2007 and begin on March
31, 2007 in lieu of fees  received for attending  meetings in 2007.  Each of the
option grants  described  above will be made annually on the last trading day of
December,  provided  that the 2007  retainer  options  were  already  granted in
December 2006 and the initial grants for Committee Chairs, Committee Members and
the Vice-Chairman  were made on February 8, 2007 with the next such grants to be
made on the last trading day of December 2007. The exercise price of the options
will be equal the closing  price of the common  stock on the date of grant.  The
options will vest on the first  anniversary  of the date of grant  provided that
the option  holder  remains a director as of such  anniversary,  and the options
will terminate on the sixth  anniversary of the date of grant.  The options will
be granted under the 2004 Stock Option Plan.EXHIBIT 10.37

                            N O W T H E R E F O R E,
                            - - - - - - - - - - - -

In consideration of the premises and the mutual covenants  contained herein, and
for other good and valuable consideration,  the receipt and sufficiency of which
is hereby acknowledged, the parties hereto agree as follows:

1. The  Company  shall pay  Kuslima  Shogen an amount  equal to 15% of any gross
royalties  which may be paid to the Company from any license(s)  with respect to
the Company's  principal  product,  ONCONASE(TM),  or any other products derived
from amphibian source extract, produced either as a natural, synthesized, and/or
genetically  engineered  drug for which the Company owns or is a co-owner of the
Patent,  or acquires  such right in the  future,  for a period not to exceed the
life of the Patents. In the event the Company manufactures and markets the drugs
by itself,  then the  Company  will pay Kuslima  Shogen an amount  equal to five
percent  (5%) of gross  sales  from any  products  sold  during  the life of the
Patents.

2. This agreement does not amend the Employment Agreement between Kuslima Shogen
and the Company dated  September 1, 1987, but rather is a separate  supplemental
agreement between the parties.

IN WITNESS WHEREOF,  the parties hereto have executed this Agreement the day and
year first above written.

ATTEST:                                   ALFACELL CORPORATION
/s/ Linda McCarthy                        By:  /s/ Alan W. Bell

WITNESS:
/s/ Ina Siegel                            /s/ Kuslima Shogen

<PAGE>

NOW THEREFORE on this date April 16, 2001

In consideration of the premises and the mutual covenants  contained herein, and
for other good and valuable consideration,  the receipt and sufficiency of which
is hereby acknowledged, the parties hereto agree to amend the attached agreement
dated July 24, 1991 between Alfacell Corporation and Kuslima Shogen.

The Board of Directors and Kuslima  Shogen have on several  occasions  discussed
amending and updating  Alfacell and Shogen's  royalty  agreement  dated July 24,
1991 to  encompass  the  changing  global  healthcare  market and to clarify the
original agreement for proper interpretation.

The spirit of the amended  agreement  is for Shogen to receive 15% of  royalties
Alfacell  is paid from any  license(s)  with  respect  to  Alfacell's  principal
product  Onconase(R),  or any  other  products  derived  from  amphibian  source
extract,  produced  either  as  a  natural,   synthesized,   and/or  genetically
engineered  drug for which the company owns or is co-owner of the patent,  for a
period not to exceed the life of the patents.

No royalties would be paid if Alfacell does not own or co-own patent rights. Any
product rights obtained by Alfacell that does not fit the above definition would
be royalty free with no payments to Shogen.

In the event  Alfacell  manufactures  and markets the drugs by itself,  then the
company will pay Kuslima  Shogen an amount equal to five percent (5%) of the net
sales from any products sold during the life of the patents.

The  spirit  of  the   agreement   also   provides   that  there   would  be  no
"double-dipping".  That is Shogen would receive  payment from license(s) or from
product sales but not both,  unless  Alfacell and a Licensee(s)  both market the
licensed product.

Alfacell and Shogen agree to binding  arbitration  should a dispute  arise.  All
disputes arising under this Agreement will be resolved by arbitration  conducted
in  accordance  with  the  International  Commercial  Arbitration  Rules  of the
American  Arbitration  Association.  The place of arbitration  will be New York,
N.Y. The  arbitration  panel will consist of three  arbitrators,  one arbitrator
appointed by the Board of Directors of Alfacell,  one  appointed by Shogen,  and
the third  arbitrator  be appointed by the two  arbitrators  so appointed by the
Parties.

Clarification of Terms:

"Net Sales" means the amount of the gross invoiced sales of any product (only in
finished  product  form)  charged  by  Alfacell  Company,   its  affiliates  and
sub-licensees,  at arm's length to independent third parties, less deductions of
returns  (including  allowances  actually given for spoiled damaged,  out-dated,
rejected,  returned  product  sold,  withdrawals  and  recalls,  rebates  (price
reductions,  rebates  to social and  welfare  systems,  chargebacks,  government
mandated rebates and similar types of rebates e.g. P.P.R.S.,

<PAGE>

Medicaid),  volume  (quantity)  discounts,  outward  freights,  postage charges,
transportation  insurance,  packaging  materials  for dispatch of goods,  custom
duties, bad debts,  discounts granted later than at the time of invoicing,  cash
discounts,  taxes (value added or sales taxes,  government mandated  exceptional
taxes and other taxes directly linked to the gross sales amount), as computed on
a product  by product  bases in  Alfacell  Company's  sales  statistics  for the
countries  concerned,  using  the  internal  foreign  currency  translation  the
Alfacell's then current standard  practices  actually used on a consistent basis
preparing its audited financial statements.

"Royalties"  are  defined as  payments  received  from  independent  parties for
licensed  product sales falling under the definition of covered product sales in
this agreement.

In Witness Whereof,  the parties hereto have executed this Agreement the day and
year first above written.

Attest:                                   Alfacell Corporation

/s/  Stanislaw Mikulski                   By:  /s/  Donald R. Conklin
-----------------------                        ----------------------

                                          /s/  Kuslima Shogen
                                          -------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]